You may not expect to find an ivory tower academic whose erudite specialty is philosophy hanging out at drug marketing conferences, but that’s where you would have found Dr. Sergio Sismondo a few years ago. The professor of philosophy at my old stomping ground, Queen’s University in Kingston, Ontario, turned up at the annual meeting of the International Society of Medical Planning Professionals, one of two large organizations representing medical communications firms.
A medical communications firm is a business that sells services to pharmaceutical and other companies for “managing” the publication and placement of scientific research papers for maximal marketing impact, often running a full publicity campaign to help sell the drug being “studied”. This is an alarmingly widespread practice in which drug companies essentially decide what your physician will end up reading in medical journals. Continue reading →
Just when we thought things couldn’t get any more slimy in the wonderful world of Big Pharma-funded medical journal articles, along comes last week’s editorial in the Canadian Medical Association Journal. Their September 9th editorial claims that somewhere between 50% and 100% of articles on drugs that appear in journals are ghostwritten, according to Dr. David Healy, a psychiatrist at the University of Cardiff in Wales and a critic of the drug industry’s influence on physicians’ drug prescribing habits. Dr. Healy further claims:
“Ghostwriting ‘crept up on’ the medical profession and became so common by the mid-90s that even senior researchers came to accept it as an ethical practice. Other critics of the practice agree, claiming that many researchers will put their name on a document as primary author even if they just edited it — or only read it and made no changes.
“If you have people like me who say they won’t do this, the pharmaceutical industry can easily go elsewhere and find a person who will.”Continue reading →